Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?

DexCom (DXCM) is poised to report Q2 2025 results on July 30, with consensus estimates forecasting revenues of $1.12 billion, an 11.8% year-over-year increase, and EPS of $0.45, up 4.7%. This anticipated growth is largely driven by expanded U.S. CGM coverage, robust international market performance, and the increasing traction of its over-the-counter Stelo device, bolstered by its Amazon launch and new partnerships. DXCM shares have gained 11.1% year-to-date, outperforming the industry, and the company maintains its full-year 2025 revenue guidance of $4.6 billion, expecting continued margin expansion.

Analysis

DexCom is positioned for a strong second-quarter 2025 earnings report, with consensus estimates projecting an 11.8% year-over-year revenue increase to $1.12 billion and a 4.7% rise in EPS to $0.45. The company's stock has significantly outperformed, gaining 11.1% year-to-date against a 10.2% decline in its industry. This performance is supported by clear growth drivers, including expanded U.S. coverage from major PBMs, which has resulted in record new patient starts, and continued international expansion, particularly in Japan and France. The launch of the Stelo over-the-counter CGM, now available on Amazon, represents a key strategic initiative to penetrate the non-insulin market and is expected to contribute 2-3% to 2025 sales. Management has reinforced this positive outlook by reiterating full-year revenue guidance of $4.6 billion and projecting margin expansion. However, a note of caution is warranted, as the company has a mixed earnings surprise history, having missed estimates last quarter, and its current Earnings ESP of 0.00% does not statistically increase the probability of an earnings beat, despite a favorable Zacks Rank #2 (Buy).

Key Decisions for Investors

• Given the strong fundamental growth drivers, including expanded U.S. coverage and the strategic launch of the Stelo device, investors may view the reaffirmed full-year guidance as a sign of confidence in the long-term growth thesis.
• It is prudent to weigh the positive operational narrative against the company's mixed earnings surprise history and the neutral 0.00% Earnings ESP, which suggests an earnings beat is not a certainty and introduces a layer of risk to the Q2 report.
• Investors should closely scrutinize the upcoming results for data on new patient starts, initial sales contribution from Stelo, and any revisions to margin outlook, as these will be critical indicators of execution on its growth strategy amidst competitive pressures.